From Promising Clinical Signals to Registrational Success: Prioritizing RLT Opportunities for Late-Stage Development

• Evaluating which early clinical signals and development opportunities demonstrate sufficient clinical and commercial potential to justify progression into resource-intensive Phase II–III trials
• Assessing efficacy, safety, patient selection and competitive differentiation to distinguish programmes capable of delivering meaningful value from those entering increasingly crowded RLT landscapes
• Leveraging clinical data, competitive intelligence and evolving market dynamics to inform late-stage portfolio and investment decisions and prioritise the RLT programmes with the strongest path towards registration

Speakers:

Oystein Soug

Chief Executive Officer

Oncoinvent AS